Drugs Made In America Acquisition Corp.

Drugs Made In America Acquisition Corp. (Nasdaq: DMAA) is a blank check company organized to pursue a business combination in the pharmaceutical and healthcare sector, with a stated emphasis on domestic drug manufacturing. The company filed an amended registration statement on Form S-1/A with the SEC on December 9, 2024, continuing its IPO registration process during the 2024 filing cycle. DMAA targets opportunities within U.S.-based pharmaceutical supply chains and domestic drug production, a segment that has attracted renewed regulatory and capital-markets interest in recent years. The company has not yet announced a definitive merger target. Sign up at SpacDesk for full filing history, sponsor details, and deal analytics on DMAA and hundreds of other SPACs.